Author

R. C. Lopeman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Organism:mouse· 1

Frequent Co-Authors

A. Owen· 2 shared C. H. Caygill· 2 shared S. H. Pennington· 2 shared A. Ardrey· 1 shared A. Breen· 1 shared A. Valentijn· 1 shared D. L. Rathbone· 1 shared E. I. Patterson· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. Owen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.

H. J. Box, S. H. Pennington, E. Kijack, L. Tatham, C. H. Caygill, R. C. Lopeman, L. N. Jeffreys, J. Herriott, J. Sharp, M. Neary, A. Valentijn, H. Pertinez, P. Curley, U. Arshad, R. K. Rajoli, , A. Owen

This paper investigates probenecid's antiviral activity against SARS-CoV-2 in Vero E6 cells and Syrian golden hamsters, finding no significant inhibition of viral replication or cytopathic effects.

bioRxiv · Mar 3, 2022 · PreprintPharmacology & Toxicology

Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2

L. Jeffreys, S. H. Pennington, J. Duggan, C. H. Caygill, R. C. Lopeman, A. Breen, J. Jinks, A. Ardrey, S. Donnellan, E. I. Patterson, G. I. Hughes, W. D. Hong, P. M. O'Neill, G. Aljayyoussi, A. Owen, , G. A. Biagini

This study shows that combining remdesivir and ivermectin enhances antiviral activity against SARS-CoV-2 in vitro.

bioRxiv · Dec 23, 2020Microbiology

Combining amoxicillin and relebactam provides a new therapeutic option for Mycobacterium abscessus infection

R. C. Lopeman, J. Harrison, S. E. R. Gibson, D. L. Rathbone, M. Desai, P. A. Lambert, J. A. G. Cox

This paper shows that combining amoxicillin and relebactam synergistically inhibits Mycobacterium abscessus through non-competitive inhibition of its beta-lactamase, offering a new therapeutic option for infections.

bioRxiv · Apr 17, 2019 · PreprintMicrobiology